...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hormone molecular biology and clinical investigation. >Evaluation of Clinical, Laboratory and Treatment Modalities in C3 Glomerulopathy: Single Center Experience
【24h】

Evaluation of Clinical, Laboratory and Treatment Modalities in C3 Glomerulopathy: Single Center Experience

机译：临床、实验室的评估和治疗在C3 Glomerulopathy模式:单中心经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/aim: C3 glomerulopathy (C3GP) defines a rare group of glomerulonephritis (GN), which could lead to end stage renal disease (ESRD). Histopathologic features of the disease have yet to be defined and the prognostic factors and optimal treatment are not fully known. The purpose of this study was to determine the demographic, histological change, treatment modalities and outcomes among patients with C3GP.Material and method: This retrospective observational study was conducted in the Department of Nephrology, Gazi University, Ankara, from 2013 to 2017. All patients with kidney biopsies fulfilling the criteria for C3GP were included in the study.Results: Twenty-four patients with C3GP (50% male and of middle age - 43 years old) were enrolled in this study. 21% (5/24) patients developed ESRD. Renal biopsy findings such as crescent formation, glomerulo-sclerosis and tubular atrophy were similar in patients with ESRD, when compared to patients who did not develop ESRD. The treatment modalities of the patients were examined in two groups as MMF based and non-MMF based. The difference in the preservation of eGFR did not reach statistical significance between these two groups. The success rate of complete remission was similar between both groups. Serum creatinine levels >2.3 mg/dl at admission and need for renal replacement treatment (RRT) were associated with decreased renal survival.Conclusion: MMF based or non-MMF based treatments have similar efficacy in C3GP. Serum creatinine level higher than 2.3 mg/dl at the time of diagnosis and need for RRT during admission are a strong predictor of ESRD with high sensitivity and specificity.
机译：背景/目的:C3 glomerulopathy (C3GP)定义了一个罕见的肾小球肾炎(GN)可能导致晚期肾脏疾病(ESRD)。疾病的病理特征定义和预后因素最佳的治疗目前还不完全清楚。本研究的目的是确定的人口、组织学变化、治疗患者之间的形式和结果C3GP。进行了观察研究美国肾脏学,Gazi大学,安卡拉,从2013年到2017年。肾活检履行C3GP的标准被包括在研究。C3GP患者(50%的男性和中年-43岁)参加本研究。(5/24)发达ESRD患者。发现如新月的形成,glomerulo-sclerosis和肾小管萎缩类似的ESRD患者,相比ESRD患者没有出现。物理疗法的病人在两个检查MMF和基于non-MMF组。表皮生长因子受体没有保护的差异这两个之间达到统计学意义组。两组之间的相似。入学水平> 2.3 mg / dl和肾的必要性替代治疗(RRT)联系在一起减少肾存活率。non-MMF基础治疗也有类似的功效C3GP。mg / dl时诊断和RRT的必要性在ESRD的入学预示着具有高敏感性和特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号